An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer
Endocrinology and Metabolism Clinics of North America · 2025
DOI: 10.1016/j.ecl.2025.03.012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2025. Verfasst von Laura Boucai. Beteiligte Einrichtung: Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center - Weill Cornell Medical College, 530 East 74th Street, Suite 22…. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Iodine Radioisotopes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
Two-thirds of patients with advanced thyroid cancer are refractory to radioactive iodine (RAI). Inhibition of genetic drivers of thyroid cancer in the intracellular mitogen-activated protein kinase pathway, like BRAF, RAS, RET, and NTRK, results in increased expression of thyroid differentiation genes and the sodium-iodine symporter. Targeted therapies in combination with RAI result in structural decrease of metastatic lesions in 33% to 63% of patients that successfully take up RAI after redifferentiation. The true efficacy of targeted therapies with RAI remains to be proven in clinical trials against the efficacy of targeted therapies without RAI or against multi-kinase inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Endocrinology Service, Memorial Sloan Kettering Cancer Center - Weill Cornell Medical College, 530 East 74th Street, Suite 22244, New York, NY 10021, USA. Electronic address: boucail@mskcc.org.
Förderung
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Boucai, L. (2025). An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer. Endocrinology and Metabolism Clinics of North America. https://doi.org/10.1016/j.ecl.2025.03.012
Vancouver
Boucai L. An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer. Endocrinology and Metabolism Clinics of North America. 2025. doi:10.1016/j.ecl.2025.03.012
BibTeX
@article{Boucai2025,
author = {Boucai, Laura},
title = {An Update on Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer},
journal = {Endocrinology and Metabolism Clinics of North America},
year = {2025},
doi = {10.1016/j.ecl.2025.03.012}
}
EUVIMED